{"id":786022,"date":"2023-09-26T02:46:06","date_gmt":"2023-09-26T06:46:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/"},"modified":"2023-09-26T02:46:06","modified_gmt":"2023-09-26T06:46:06","slug":"shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/","title":{"rendered":"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials<\/b><\/p>\n<p><i>Promising outcomes indicate significant reductions in emergency visits and hospital readmissions, alongside reductions in healthcare utilization costs relating to post-MI patient treatment<\/i><\/p>\n<p>TEL AVIV, Israel &amp; ZURICH &amp; NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) (&#8220;<b>SHL<\/b>\u201d or the \u201c<b>Company<\/b>\u201d), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced).<\/p>\n<p>\nThe initial findings from both trials, which focus on the application of SHL&#8217;s patented and FDA cleared SmartHeart\u00ae 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home, have been nothing short of remarkable.<\/p>\n<p>\nKey highlights from the presentation of the initial results include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nA staggering decrease of- 27.5% in emergency room visits in the TELE-ACS trial<sup>1<\/sup>.<\/p>\n<\/li>\n<li>\nMoreover, hospital readmission rates plummeted by -55% in the TELE-ACS trial<sup>1<\/sup>.<\/p>\n<\/li>\n<li>\nIn the HELP-ME trial, cardiovascular-driven emergency department visits for patients using the SmartHeart\u00ae device were reduced to an astonishing 0 (zero)<sup>2<\/sup>.<\/p>\n<\/li>\n<li>\nCardiovascular driven rehospitalization was also at 0 (zero)<sup>2<\/sup> for patients using the device in the HELP-ME trial.<\/p>\n<\/li>\n<li>\nThe presentation at the conference noted that the HELP-ME trial demonstrated the potential of SHL&#8217;s system be successfully replicated in the US medical system, emphasizing its capability to reduce non-indicated cardiovascular emergency department visits and hospitalizations while improving early recognition of serious cardiovascular presentations.<\/p>\n<\/li>\n<\/ul>\n<p>\nErez Nachtomy, CEO of SHL Telemedicine, commented, &#8220;The initial results from the HELP-MI and TELE-ACS trials have surpassed our expectations. We are extremely confident in the potential of our SmartHeart\u00ae technology, and these findings further validate its efficacy in post-MI patient care. We are looking forward to the continued positive impact our technology will have on telemedicine and remote patient care.&#8221;<\/p>\n<p><b>Presentations of the trials from the VPM 2023 conference are available at:<br \/>\n<br \/><\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.millbrook-events.co.uk%2FVPM2023&amp;esheet=53560487&amp;newsitemid=20230925392069&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.millbrook-events.co.uk%2FVPM2023&amp;index=1&amp;md5=bfd4a598c9230f0053e0fe0e55b712e4\">https:\/\/www.millbrook-events.co.uk\/VPM2023<\/a><\/p>\n<p><b>About SHL Telemedicine<br \/>\n<br \/><\/b>SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.shl-telemedicine.com&amp;esheet=53560487&amp;newsitemid=20230925392069&amp;lan=en-US&amp;anchor=www.shl-telemedicine.com&amp;index=2&amp;md5=87b94c1ce408b4bb1769af35cdf36690\">www.shl-telemedicine.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<br \/>\n<br \/><\/b><i>Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.<\/i><\/p>\n<p><sup>1<\/sup> Telemedicine group vs. control standard care group at 3 months follow-up<br \/>\n<br \/><sup>2<\/sup> Telemedicine group compliant users vs. control group<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230925392069\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230925392069\/en\/<\/a><\/span><\/p>\n<p><b>For further information please contact:<br \/>\n<\/b><br \/>Fabienne Farner, IRF, Phone : +41 43 244 81 42, <a rel=\"nofollow\" href=\"mailto:farner@irf-reputation.ch\">farner@irf-reputation.ch<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New York Switzerland United States North America Middle East Israel Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Technology Telemedicine\/Virtual Medicine Data Management Other Health Technology Apps\/Applications Managed Care Biometrics Medical Devices Hospitals Clinical Trials Other Technology Cardiology Telecommunications Biotechnology Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230925392069\/en\/1897840\/3\/download_%282%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials Promising outcomes indicate significant reductions in emergency visits and hospital readmissions, alongside reductions in healthcare utilization costs relating to post-MI patient treatment TEL AVIV, Israel &amp; ZURICH &amp; NEW YORK&#8211;(BUSINESS WIRE)&#8211; SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) (&#8220;SHL\u201d or the \u201cCompany\u201d), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced). The initial findings from both trials, which focus on the application of SHL&#8217;s patented and FDA cleared SmartHeart\u00ae 12-lead ECG technology &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-786022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHL Telemedicine&#039;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHL Telemedicine&#039;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials Promising outcomes indicate significant reductions in emergency visits and hospital readmissions, alongside reductions in healthcare utilization costs relating to post-MI patient treatment TEL AVIV, Israel &amp; ZURICH &amp; NEW YORK&#8211;(BUSINESS WIRE)&#8211; SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) (&#8220;SHL\u201d or the \u201cCompany\u201d), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced). The initial findings from both trials, which focus on the application of SHL&#8217;s patented and FDA cleared SmartHeart\u00ae 12-lead ECG technology &hellip; Continue reading &quot;SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-26T06:46:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials\",\"datePublished\":\"2023-09-26T06:46:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/\"},\"wordCount\":582,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/\",\"name\":\"SHL Telemedicine's SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-09-26T06:46:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHL Telemedicine's SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/","og_locale":"en_US","og_type":"article","og_title":"SHL Telemedicine's SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials - Market Newsdesk","og_description":"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials Promising outcomes indicate significant reductions in emergency visits and hospital readmissions, alongside reductions in healthcare utilization costs relating to post-MI patient treatment TEL AVIV, Israel &amp; ZURICH &amp; NEW YORK&#8211;(BUSINESS WIRE)&#8211; SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) (&#8220;SHL\u201d or the \u201cCompany\u201d), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced). The initial findings from both trials, which focus on the application of SHL&#8217;s patented and FDA cleared SmartHeart\u00ae 12-lead ECG technology &hellip; Continue reading \"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-26T06:46:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials","datePublished":"2023-09-26T06:46:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/"},"wordCount":582,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/","name":"SHL Telemedicine's SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-09-26T06:46:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230925392069r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shl-telemedicines-smartheart-technology-shows-remarkable-effects-in-mayo-clinic-and-imperial-college-london-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHL Telemedicine&#8217;s SmartHeart\u00ae Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=786022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=786022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=786022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=786022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}